Sanofi sees higher earnings as blockbuster skin drug soars
In 2021, blockbuster eczema treatment Dupixent was the main growth driver for French Sanofi, and the company forecasts a bright 2022 for the drug.
By Tim Loh, bloomberg
Sanofi forecast double-digit profit growth for 2022 as blockbuster therapy Dupixent extends its reach in the US and Europe.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
